Replies to post #180 on Don't Bite The Hand That Feeds You

[eye_ater]

Brean Murray initiates CYTR with a Buy and price target of $3 given CytRx's non-existent enterprise value, investors are giving no value to its pipeline of six clinical-stage drugs and several preclinical programs. The firm says the current valuation is even lower than the value of its current net cash plus its stake in RXi. They also believe that their mere market valuation for the RXi stake is extremely conservative, considering that Sirna Therapeutics and Alnylam have clearly demonstrated large pharma's interest in therapeutic RNAi.
http://news.moneycentral.msn.com/provider/providerarticle.aspx?feed=BCOM&date=20080612&id=8767004